CANASA Drug Patent Profile

Which patents cover Canasa, and when can generic versions of Canasa launch?

Canasa is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in twelve countries.

The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Canasa

A generic version of CANASA was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Summary for CANASA

International Patents:	13
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	178
Clinical Trials:	2
Patent Applications:	4,069
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for CANASA
Drug Sales Revenues:	Drug sales revenues for CANASA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CANASA
What excipients (inactive ingredients) are in CANASA?	CANASA excipients list
DailyMed Link:	CANASA at DailyMed

See drug prices for CANASA

See drug sales revenues for CANASA

Recent Clinical Trials for CANASA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sandoz	Phase 3
Forest Laboratories	Phase 3
Axcan Pharma	Phase 3

See all CANASA clinical trials

Pharmacology for CANASA

Drug Class

Aminosalicylate

Paragraph IV (Patent) Challenges for CANASA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CANASA	Suppository	mesalamine	1000 mg	021252	1	2013-05-24

US Patents and Regulatory Information for CANASA

CANASA is protected by two US patents.

Patents protecting CANASA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-002	Nov 5, 2004	AB	RX	Yes	Yes			Y
Allergan	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-002	Nov 5, 2004	AB	RX	Yes	Yes			Y
Allergan	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-001	Jan 5, 2001		DISCN	No	No

International Patents for CANASA

See the table below for patents covering CANASA around the world.

Country	Patent Number	Title	Estimated Expiration
China	102970971	Mesalamine suppository
Canada	2784772	SUPPOSITOIRE DE MESALAMINE (MESALAMINE SUPPOSITORY)
Chile	2012001636	Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa.
Singapore	181169	MESALAMINE SUPPOSITORY